BMT CTN Protocol 1202

Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT.

Below are protocol-related documents, which may be periodically updated.

             Protocol Co-Chair: John Levine, MD (734-936-8456)

             Protocol Co-Chair: John Hansen, MD

             Protocol Officer: Wael Saber, MD

             Protocol Coordinator: Dylan Mawby (301-251-1161)

             Medical Monitor: Wael Saber, MD



The BMT CTN is committed to including widespread transplant community participation in these trials. For information on how to apply to participate on this study, please contact the Protocol Coordinator Dylan Mawby at for details.